|
Media Materials (12 June 2008)
Prof. Zhao-You Tang said, Hong Kong - Shanghai International Liver Congress is a platform to enhance understanding of viral hepatitis and to link up Chinese and the International Medical Communities
湯釗猷教授表示:「港滬國際肝病會議是提高對肝炎病毒理解及強化中國與國際醫療組織連繫的平台。」
Prof. George K.K. Lau, President of APASL and the Secretary General of the Hong Kong - Shanghai International Liver Congress said, "CHB is most prevalent in the Asia-Pacific region where 75 percent of the world's 350 million chronic carriers reside and China is one of the most heavily impacted countries with about 93 million people afflicted with CHB."
APASL會長兼港滬國際肝病會議秘書長廖家傑教授表示：「乙肝在亞太地區非常普遍，全世界有3億5千萬慢性乙肝帶菌者。當中，75%在亞太區居住。中國是其中一個深受影響的國家，約有9千3百萬人帶有乙肝病毒。」
Prof. Hou remarked, "The on-treatment 24-week HBV DNA monitoring is a useful indicator for clinicians to predict success of a treatment, enabling them to implement an alternative strategy if necessary. It allows us time to adjust treatment before the disease progresses.
侯金林教授表示：「臨床醫生可根據治療第24周的病毒數量去預計所採用的治療方法是否達到預期效果，在有需要的情況下，改用另一種療法。此舉令醫生在患者病情惡化之前，有時間調整治療對策。
Mr. Kei is very thankful for Prof. Lau's care and concern while he is suffering from chronic hepatitis B.
紀伯非常感謝廖教授對他病情的關注。
Mr. Kei talks about living with chronic hepatitis B and his pursuit for treatment.
紀伯細述發現感染乙肝後尋找適當治療的過程。
back to Media Center
|
